Cargando…
Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues
Progesterone antagonist RU486 (mifepristone) has been implicated for many anti-neoplastic and obstetrical applications. But the compound has demonstrated undesired agonist-like effect depending on cell, tissue and species studied. Using PR-transfected breast cancer cells MDA-MB-231, this report desc...
Autores principales: | Lin, V C-L, Aw, S E, Ng, E H, Ng, E H-L, Tan, M G-K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364017/ https://www.ncbi.nlm.nih.gov/pubmed/11747343 http://dx.doi.org/10.1054/bjoc.2001.2167 |
Ejemplares similares
-
RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion
por: Yu, Suhong, et al.
Publicado: (2019) -
Novel Melatonin, Estrogen, and Progesterone Hormone Therapy Demonstrates Anti-Cancer Actions in MCF-7 and MDA-MB-231 Breast Cancer Cells
por: Hasan, Mahmud, et al.
Publicado: (2020) -
Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity
por: DeBono, Aaron, et al.
Publicado: (2019) -
PGRMC1 Inhibits Progesterone-Evoked Proliferation and Ca(2+) Entry Via STIM2 in MDA-MB-231 Cells
por: Cantonero, Carlos, et al.
Publicado: (2020) -
The progesterone antagonist mifepristone/RU486 blocks the negative effect on life span caused by mating in female Drosophila
por: Landis, Gary N., et al.
Publicado: (2015)